Related Experiment Video
Updated: Dec 24, 2025

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
Novel therapies for septic shock over the past 4 decades
Anthony F Suffredini1, Robert S Munford
1Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD 20892, USA. asuffredini@cc.nih.gov
Abstract:
Infections that result in shock and organ failure are a major public health problem worldwide. Severe sepsis and septic shock affect patients of all ages and often complicate chronic diseases. They are the major causes of death in critical care units and contribute substantially to hospital inpatient costs. Translating the scientific advances of the last 4 decades into clinical practice has been challenging. Despite many attempts to develop new therapies, the basic elements of treatment have not changed since the 1960s. In this Grand Rounds, we summarize the results of the clinical trials conducted during the last 4 decades, discuss some lessons learned, and suggest possible directions for future investigation.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Acute Pyelonephritis II: Diagnostic Studies and Management
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure VI: Adjunct Therapies
Acute Coronary Syndrome IV: Interprofessional Care
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

